Therapeutic Dose Range of Mirtazapine
The therapeutic dose range of mirtazapine is 15 to 45 mg per day, administered orally as a single evening dose. 1
FDA-Approved Dosing
The FDA label provides clear dosing parameters:
- Starting dose: 15 mg once daily, preferably in the evening before sleep
- Maximum dose: 45 mg per day
- Dose titration: Changes should not occur more frequently than every 1-2 weeks to allow adequate assessment of response 1
If patients fail to respond adequately to the initial 15 mg dose, the dose should be increased up to the maximum of 45 mg daily 1.
Clinical Trial Evidence
In the pivotal efficacy trials that established mirtazapine's antidepressant effects, patients were titrated within a dose range of 5-35 mg/day, with mean doses for study completers ranging from 21-32 mg/day 1. These studies demonstrated superiority over placebo across multiple depression rating scales.
Dosing Considerations
Age and gender significantly affect mirtazapine pharmacokinetics:
- Elderly patients: Oral clearance is reduced by 40% in elderly males and 10% in elderly females compared to younger patients 1
- Female patients: Exhibit significantly longer elimination half-lives (37 hours) compared to males (26 hours) 1
Renal impairment requires dose adjustment:
- Moderate impairment (GFR 11-39 mL/min/1.73 m²): 30% reduction in clearance
- Severe impairment (GFR <10 mL/min/1.73 m²): 50% reduction in clearance 1
Hepatic impairment: Decreases oral clearance by approximately 30% 1
Drug Interactions Requiring Dose Modification
The FDA label specifies dose adjustments for specific drug interactions 1:
- Strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin): May require dose increase
- Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): May require dose decrease
- Cimetidine: May require dose decrease
Common Pitfall
A critical caveat: Higher doses (above 45 mg) were studied in some clinical trials 2, 3, with one study using up to 60 mg/day 2. However, the FDA-approved maximum remains 45 mg/day for outpatient use in the United States 1. The 15-45 mg range represents the established therapeutic window balancing efficacy and safety.
Gradual dose reduction is essential when discontinuing to minimize withdrawal symptoms 1.